Therapies for cirrhosis include efforts to reduce the incidence of cirrhosis and its complications as well as those which address the symptoms of cirrhosis. Both approaches are unified by the goal of reducing the public and personal burden posed by cirrhosis. This review highlights the current standard of care and the opportunities to improve it. Improvements in the quality and quantity of life experienced by patients with cirrhosis will require efforts towards the implementation of evidence-based therapies and the execution of patient-centred trials.
Guarantor of the article
Declaration of personal interests
Tapper has consulted for Bausch, Mallinckrodt, Axcella, Novo Nordisk, Ambys, Lipocine, Kaleido, Takeda.
Elliot Tapper receives funding from the National Institutes of Health. NNU is supported by a Clinical, Translational and Outcomes Research Award from the American Association of the Study of Liver Diseases. R.L. receives funding support from NIAAA (U01AA029019), NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (U01DK130190, U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318), NHLBI (P01HL147835) and DOD PRCRP (W81XWH-18-2-0026). RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. D.Q.H. receives funding support from Singapore Ministry of Health's National Medical Research Council under its NMRC Research Training Fellowship (MOH-000595-01). In addition, he has served as an advisory board member for Eisai.
Data Availability Statement
Not applicable to a review.
Aliment Pharmacol Ther. 2022;55(9):1099-1115. © 2022 Blackwell Publishing